Medicare GLP-1 Bridge 2026: who qualifies for $50/month coverage

What the Medicare GLP-1 Bridge actually is

Starting July 1, 2026, Medicare will let eligible Part D beneficiaries get certain GLP-1 medications for a $50 monthly copay. The program is called the Medicare GLP-1 Bridge, and CMS confirmed the details in a press release announcing the initiative.

It ends December 31, 2027. CMS is blunt about this: the official CMS program page calls it a “short-term demonstration” and a “pilot program.” Not a permanent change to what Part D covers. A test with an expiration date.

The legal basis matters too. CMS isn’t using its Innovation Center authority, the mechanism behind many other Medicare pilots. The Bridge runs instead under Section 402(a)(1)(A) of the Social Security Amendments of 1967, applied to Part D through Section 1860D-42(b) of the Social Security Act. That’s the Secretary’s general demonstration authority. The distinction is technical, but it explains why the program can be stood up and wound down without new legislation.

CMS frames the goal as testing “the impacts of increased access to GLP-1 drugs for weight management on the Medicare program,” according to the CMS launch announcement. That word “test” is doing real work. This is a data-collection exercise as much as a coverage expansion.

Which drugs are covered

Not every GLP-1 qualifies. Per Medicare.gov’s weight loss drug coverage page, only three products do:

• Foundayo (tablet)
• Wegovy (injection or tablet)
• Zepbound, KwikPen form only

Zepbound single-dose vials and single-dose pens are explicitly excluded. If your prescription is one of those formats, the $50 copay doesn’t apply, even though Zepbound itself is on the list.

One scope note: this article covers program mechanics only. It doesn’t evaluate how well these drugs work or compare their safety profiles. For that, talk to your doctor or read the FDA labeling directly. If you want background on oral options specifically, see our piece on oral semaglutide versus the Wegovy injection.

Who qualifies

Eligibility runs on a tiered BMI-plus-comorbidity system, per Medicare.gov. You must be 18 or older and meet one of three tiers at the start of treatment:

1. BMI 35 or higher: no additional condition required.
2. BMI 30 or higher, plus one of: diastolic heart failure (HFpEF), uncontrolled hypertension, or stage 3a or higher chronic kidney disease.
3. BMI 27 or higher, plus one of: prediabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease.

These are Bridge-specific criteria CMS set for this demonstration. They are not the FDA label indications for these drugs, so don’t assume they match what a doctor would use to prescribe a GLP-1 outside the program.

A prescribing provider also has to certify that you’re using the drug as part of a lifestyle program built around diet and exercise, and must complete prior authorization when the plan requests it, per the same Medicare.gov page.

Who’s excluded, and this is the part people miss

Here’s where the Bridge catches beneficiaries off guard. You are not eligible if you already get GLP-1 coverage through your regular Part D plan, or if you have any of the following, according to Medicare.gov:

• Type 2 diabetes
• Moderate-to-severe sleep apnea
• Fatty liver disease

The diabetes exclusion is the big one. Plenty of people assume a GLP-1 access program would obviously include diabetics, since these drugs are widely used for glucose control. It doesn’t. If you have type 2 diabetes, the Bridge isn’t your pathway. Your standard Part D plan may already cover a GLP-1 for that condition, and that’s a separate, existing route. Check with your plan directly.

The same logic covers sleep apnea and fatty liver disease. If your Part D plan already covers GLP-1 treatment for those indications, that coverage sits outside the Bridge and isn’t affected either way.

How the $50 copay actually works

This isn’t a normal Part D copay. Per the CMS program page, the $50 goes directly to the pharmacy for a one-month supply (28 or 30 days, depending on the drug), and it’s structured outside the standard Part D payment flow. Specifically:

• It does not count toward your Part D deductible.
• It does not count toward true out-of-pocket (TrOOP) costs.
• It will not appear on your Part D Explanation of Benefits or Medicare Summary Notice.
• It cannot be reduced through Extra Help or the Low-Income Subsidy program.
• It cannot be spread across months using the Medicare Prescription Payment Plan.

In practice, $50 is a flat monthly cost, full stop. It doesn’t interact with the rest of your Part D benefit design the way normal drug costs do. If you track deductible progress or TrOOP totals, this charge won’t appear in those calculations.

If the Bridge doesn’t apply to you, or you’re weighing what unsubsidized GLP-1s cost, our guides on GLP-1 coupons and discounts and paying for GLP-1s without insurance cover those alternatives.

Which plans offer it

The Bridge isn’t limited to one type of Part D plan. Per Medicare.gov, it’s available across:

• Standalone Medicare drug plans (PDP)
• Medicare Advantage plans with drug coverage (MA-PD), including HMO, HMOPOS, and Local/Regional PPO
• Special Needs Plans (SNP)
• Employer/union group waiver plans (EGWP)
• The Limited Income Newly Eligible Transition (LI NET) program

If you’re enrolled in any Part D-adjacent plan type, the Bridge is potentially available to you, assuming you meet the clinical criteria above.

What happens if you get approved

Once your prior authorization goes through, it stays valid through December 31, 2027, including refills and dose changes, per Medicare.gov. One exception: switching to a different GLP-1 drug requires new authorization. So a changing Wegovy dose shouldn’t trigger re-certification, but a switch from Wegovy to Zepbound resets the clock.

Why the program ends in 2027, and what’s next

CMS ties the Bridge’s end date to a related initiative: the BALANCE Model (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth), meant to expand GLP-1 and lifestyle-intervention access for Medicare and Medicaid beneficiaries over the longer term. BALANCE isn’t launching in 2027, so CMS extended the Bridge through the end of that year, partly to keep collecting GLP-1 utilization data before BALANCE potentially rolls into Part D.

What happens after December 31, 2027? No CMS material reviewed for this article addresses it. The Bridge may hand off to BALANCE, coverage may lapse, or something else may replace it. Genuinely open question, and not one to guess at.

Frequently Asked Questions

Is the Medicare GLP-1 Bridge a permanent Medicare benefit? No. CMS calls it a short-term demonstration and pilot program, running July 1, 2026 through December 31, 2027, under the Secretary’s Section 402 demonstration authority rather than a permanent statutory expansion of Part D.

Can I use the $50/month program if I have type 2 diabetes? No. Medicare.gov excludes beneficiaries with type 2 diabetes, along with moderate-to-severe sleep apnea and fatty liver disease. If you have type 2 diabetes, check whether your standard Part D plan already covers a GLP-1 for that condition. That’s a separate, existing pathway, not this program.

Does the $50 copay count toward my Part D deductible or out-of-pocket maximum? No. The payment sits outside the normal Part D benefit flow. It doesn’t count toward your deductible or TrOOP, won’t show up on your Part D EOB or Medicare Summary Notice, and can’t be reduced through Extra Help/LIS or spread out with the Medicare Prescription Payment Plan.

What BMI do I need to qualify? It’s tiered. BMI 35+ qualifies on its own. BMI 30+ qualifies with HFpEF, uncontrolled hypertension, or stage 3a+ chronic kidney disease. BMI 27+ qualifies with prediabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease. These are Bridge-specific thresholds, not general FDA label criteria for the individual drugs.

Which specific drug products are covered? Three: Foundayo (tablet), Wegovy (injection or tablet), and Zepbound in KwikPen form only. Zepbound single-dose vials and single-dose pens are not covered under the Bridge.

What happens after December 31, 2027? Unclear. CMS connects the Bridge’s timeline to the not-yet-launched BALANCE Model, suggesting one may lead into the other, but no CMS source says what beneficiaries should expect for 2028 coverage. Treat this as unresolved rather than assuming continuity.

This article is for informational purposes only and is not medical advice. Talk to your healthcare provider before starting, stopping, or changing any medication.